by 
Acute bacterial skin and skin structure infections (ABSSSI) refers to various bacterial infections of the epidermis, dermis, subcutaneous tissue and deeper soft tissue. Some of the common ABSSSI includes cellulitis, infected ulcers, major cutaneous abscesses and wound infections. Conventional antibiotics such as cephalosporins, carbapenems and aminoglycosides are widely used to treat ABSSSI. With rising prevalence of antibiotic resistance, newer generation antibiotics drugs with less chances of drug resistance have been developed which provide fast symptomatic relief from ABSSSI. The global Acute Bacterial Skin and Skin Structure Infections Market is estimated to be valued at US$ 3,466.6 Mn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics: The increasing prevalence of skin infections due to growing antibiotic resistance is a major driver fueling the growth of the acute bacterial skin and skin structure infections market. According to the Centers for Disease Control and Prevention (CDC), annually over 2 million people acquire antibiotic-resistant infections in the US alone, of which more than 23,000 patients die. Development and commercialization of newer generation antibiotics with less chances of drug resistance is another key driver boosting the acute bacterial skin and skin structure infections market growth over the forecast period. These new drugs provide quick relief from skin infections and have a broad spectrum of activity against multi-drug resistant strains of bacteria. The drivers mentioned above are thus expected to propel the acute bacterial skin and skin structure infections market expansion during the forecast period.
Segment Analysis
The acute bacterial skin and skin structure infections market can be segmented based on disease type, treatment type, distribution channel, and region. By disease type, the market is segmented into impetigo, cellulitis, boils, and others. Among these, the boils segment dominates owing to its high prevalence globally. By treatment type, the market is divided into antibiotics, anti-inflammatory and analgesics drugs. The antibiotics segment holds a major share as they are the first line of treatment for these infections.
PEST Analysis
Political: Government bodies worldwide are taking initiatives to spread awareness regarding skin infections. They are conducting campaigns to educate people about hygiene and prevention methods.
Economic: Rising healthcare expenditure and growing income levels in developing nations are contributing to market growth. However, patent expiries of major drugs pose a challenge.
Social: Changing lifestyles with less physical activity and increased stress levels have led to rise in cases of skin infections. Social media influence is also driving self-medication.
Technological: Advancements in drug delivery systems help improve treatment effectiveness and compliance. New drug formulations with fewer side effects are being researched.
Key Takeaways
The global acute bacterial skin and skin structure infections market is expected to witness high growth.
Regional analysis: The North American region currently dominates owing to the rising prevalence of chronic diseases and growing geriatric population.
Key players related content comprises Key players operating in the acute bacterial skin and skin structure infections market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc. The market is expected to be highly consolidated with key players mainly focusing on new product launches and approvals to strengthen their position. For instance, in June 2022, Melinta Therapeutics, Inc. received FDA approval for Baxdela for the treatment of acute bacterial skin and skin structure infections.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
